Autres langues Celltrion, Inc.

Actions

A068270

KR7068270008

Recherche biotechnologique et médicale

Cours en clôture Korea S.E. 02/10/2026			Varia. 5j.	Varia. 1 janv.
182 600,00 ^KRW	-0,54%		+2,93%	+5,93%

29/09	Celltrion va racheter pour 100 milliards de wons d’actions ordinaires	MT
29/09	Celltrion, Inc. autorise un programme de rachat d’actions.	CI

Autres langues

29/09	Celltrion to Repurchase KRW100 Billion of Common Shares
29/09	Celltrion, Inc. authorizes a Buyback Plan.
29/09	Celltrion, Inc. announces an Equity Buyback for 560,853 shares.
29/09	Celltrion to Seek New Drug, CDMO Partners at Milan Trade Show
29/09	Celltrion to Repurchase KRW100 Billion of Treasury Stock
23/09	Celltrion Wins US FDA Nod for RA Trial of Zymfentra
22/09	Celltrion Renews EU-GMP Certification at Songdo Campus, Expands Production Capacity
21/09	Celltrion, Inc.(KOSE:A068270) dropped from S&P International 700
21/09	Celltrion, Inc.(KOSE:A068270) dropped from S&P Global 1200
16/09	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on August 31, 2026.
16/09	Celltrion Repurchases KRW100 Billion in Shares
14/09	Celltrion, Inc.'s Equity Buyback announced on August 31, 2026, has closed with 544,299 shares, representing 0.23% for KRW 99,999.9 million.
07/09	Kospi in forte rialzo, volano i titoli dei chip
07/09	Celltrion Secures IND Application Amendment Approvals for CT-P44, CT-P51 Phase 3 Trial
31/08	Celltrion, Inc. authorizes a Buyback Plan.
31/08	Celltrion, Inc. announces an Equity Buyback for 524,384 shares.
31/08	Celltrion to Repurchase 100 Billion Won in Treasury Shares from Sept. 1
25/08	Celltrion Launches Omlyclo 300 Mg Strength In Key European Markets
24/08	Celltrion Submits Marketing Application for Keytruda Biosimilar in South Korea
18/08	Celltrion's Acquired French Healthcare Firm Becomes Fully Operational
14/08	Celltrion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Celltrion Files Phase 3 Trial Amendment for CT-P44 Biosimilar for Myeloma
27/07	Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability
24/07	Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55
24/07	Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug